Jay S. Duker Eye Point Pharmaceuticals, Inc. (EYPT) insider trading activity

Jay S. Duker is President and CEO of EyePoint Pharmaceuticals, Inc.. Currently has a direct ownership of 9,965 shares of EYPT, which is worth approximately $98,254. The most recent transaction as insider was on Jul 10, 2025, when has been sold 7,688 shares (Common Stock) at a price of $11.06 per share, resulting in proceeds of $85,029. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 9.97K

82.71% 3M change

73.79% 12M change

Total Value Held $98,254

Jay S. Duker Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 10 2025	SELL Payment of exercise price or tax liability	$85,029 $11.06 p/Share	7,688 Reduced 43.55%	9,965 Common Stock
Jul 10 2025	BUY Exercise of conversion of derivative security	-	16,667 Added 48.56%	17,653 Common Stock
Jun 23 2025	SELL Other acquisition or disposition	$465,219 $8.21 p/Share	56,665 Reduced 98.29%	986 Common Stock
Mar 19 2025	SELL Other acquisition or disposition	$123,200 $6.16 p/Share	20,000 Reduced 25.76%	57,651 Common Stock
Feb 09 2025	SELL Payment of exercise price or tax liability	$13,357 $6.5 p/Share	2,055 Reduced 2.58%	77,651 Common Stock
Feb 09 2025	BUY Exercise of conversion of derivative security	-	7,000 Added 8.07%	79,706 Common Stock
Jan 06 2025	SELL Payment of exercise price or tax liability	$53,017 $8.68 p/Share	6,108 Reduced 7.75%	72,706 Common Stock
Jan 06 2025	BUY Exercise of conversion of derivative security	-	20,794 Added 20.88%	78,814 Common Stock
Jan 05 2025	SELL Payment of exercise price or tax liability	$82,657 $8.26 p/Share	10,007 Reduced 14.71%	58,020 Common Stock
Jan 05 2025	BUY Exercise of conversion of derivative security	-	30,000 Added 30.6%	68,027 Common Stock
Jul 10 2024	SELL Payment of exercise price or tax liability	$70,032 $8.69 p/Share	8,059 Reduced 17.49%	38,027 Common Stock
Jul 10 2024	BUY Exercise of conversion of derivative security	-	16,666 Added 26.56%	46,086 Common Stock
Feb 27 2024	SELL Bona fide gift	-	2,500 Reduced 7.83%	29,420 Common Stock
Feb 20 2024	SELL Bona fide gift	-	20,000 Reduced 38.52%	31,920 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$101,750 $28.8 p/Share	3,533 Reduced 6.37%	51,920 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	-	11,967 Added 17.75%	55,453 Common Stock
Jan 06 2024	SELL Payment of exercise price or tax liability	$133,171 $20.4 p/Share	6,528 Reduced 13.05%	43,486 Common Stock
Jan 06 2024	BUY Exercise of conversion of derivative security	-	20,793 Added 29.37%	50,014 Common Stock
Feb 09 2023	SELL Payment of exercise price or tax liability	$17,297 $4.17 p/Share	4,148 Reduced 12.43%	29,221 Common Stock
Feb 09 2023	BUY Exercise of conversion of derivative security	-	11,967 Added 26.4%	33,369 Common Stock
Nov 01 2022	SELL Payment of exercise price or tax liability	$24,276 $5.42 p/Share	4,479 Reduced 17.31%	21,402 Common Stock
Nov 01 2022	BUY Exercise of conversion of derivative security	-	15,258 Added 37.09%	25,881 Common Stock
Feb 09 2022	BUY Exercise of conversion of derivative security	-	4,966 Added 31.86%	10,623 Common Stock

Also insider at

SESN

Sesen Bio, Inc. Healthcare

Director

JSD

Jay S. Duker

President and CEO

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EYPT shares.

Notify only if

Value

Insider Trading

Get notified when an Eye Point Pharmaceuticals, Inc. insider buys or sells EYPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to EyePoint Pharmaceuticals, Inc.

Track Activities on EYPT

Account